Gadolinium-primarily based distinction agents (GBCAs) are extensively used in magnetic resonance imaging (MRI) to reinforce the visibility of blood vessels, tumors, inflammation, and various inside structures. When commonly regarded Protected, concerns about GBCA toxicity have emerged over the past twenty years—notably in individuals with impaire